High-purity factor VIII concentrates produced without using monoclonal antibodies

Area of Science:

• Hematology
• Biochemistry
• Virology

Background:

• Manufacturers are enhancing the purity of Factor VIII (FVIII) concentrates.
• Purification methods like chromatography yield concentrates with specific activities ranging from 35 to 250 IU FVIII/mg protein.

Purpose of the Study:

• To evaluate the efficacy and safety of highly purified FVIII concentrates in hemophilia and von Willebrand disease patients.
• To assess the potential impact of reduced alloantigen load on human immunodeficiency virus (HIV) infection progression.
• To review the virucidal procedures and viral safety of FVIII concentrates.

Main Methods:

• Utilizing purification techniques such as gel filtration, ion-exchange, and affinity chromatography.
• Administering concentrates to hemophilia and von Willebrand disease patients.
• Implementing virucidal procedures including pasteurization or solvent/detergent treatment.
• Screening of donors and post-treatment viral marker assessment.

Main Results:

• FVIII concentrates with enhanced purity demonstrate adequate FVIII recovery and half-life in hemophiliacs.
• These concentrates increase FVIII plasma levels in von Willebrand disease patients, though normalization of bleeding time requires further study.
• Virucidal procedures effectively prevent HIV transmission; pasteurized concentrates show a low risk for viral hepatitis transmission, with solvent/detergent treated concentrates showing favorable preliminary safety data.

Conclusions:

• Highly purified FVIII concentrates are effective and safe for hemophilia treatment.
• Further research is needed to establish the normalization of bleeding time in von Willebrand disease.
• Current virucidal methods ensure a high degree of safety against viral infections like HIV and hepatitis.